Skip to content

Released May 14, 2021, before the open

10-Q filed May 14, 2021, 44 days after period end · 0001558370-21-007157

Q1 2021 · 10-Q
Revenue$11.32M−47.7% vs Q1 2020−41.9% vs Q4 2020
Net Income-$5.48MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.14N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$3,705,000N/M
Operating Cash Flow-$9,834,000N/M
Free Cash Flowderived-$10,220,000N/M
Margins · derived
Operating margin-32.7%−54.4 pt vs Q1 2020
Net margin-48.4%−56.1 pt vs Q1 2020

What the release said

The release

Same quarter

MetricQ1 2021Q1 2020Q1 2019Q1 2018
Revenue$11.32M$21.65M$10.44M$4.55M
Net Income-$5.48M$1.67M-$7.26M-$7.24M
EPS Diluted-$0.14$0.10-$0.50-$0.50

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR